This session will include a concise recap of the key changes before taking a deeper look at risk-based quality management, sponsor oversight, and data governance. It will also explore the new Annex 2, addressing novel technologies and trial types, alongside other areas that continue to generate discussion and uncertainty. Featuring Peter Twomey (Head of Inspections at the EMA).